PMC:7079862 / 27237-27739 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"953","span":{"begin":137,"end":145},"obj":"Species"},{"id":"954","span":{"begin":11,"end":17},"obj":"Chemical"},{"id":"955","span":{"begin":63,"end":72},"obj":"Chemical"},{"id":"956","span":{"begin":400,"end":409},"obj":"Chemical"},{"id":"957","span":{"begin":151,"end":157},"obj":"Disease"},{"id":"958","span":{"begin":162,"end":166},"obj":"Disease"},{"id":"959","span":{"begin":206,"end":223},"obj":"Disease"},{"id":"960","span":{"begin":251,"end":263},"obj":"Disease"},{"id":"961","span":{"begin":268,"end":283},"obj":"Disease"},{"id":"962","span":{"begin":294,"end":303},"obj":"Disease"},{"id":"963","span":{"begin":487,"end":490},"obj":"Disease"}],"attributes":[{"id":"A953","pred":"tao:has_database_id","subj":"953","obj":"Tax:9606"},{"id":"A955","pred":"tao:has_database_id","subj":"955","obj":"MESH:D001205"},{"id":"A956","pred":"tao:has_database_id","subj":"956","obj":"MESH:D001205"},{"id":"A957","pred":"tao:has_database_id","subj":"957","obj":"MESH:D018805"},{"id":"A958","pred":"tao:has_database_id","subj":"958","obj":"MESH:D012128"},{"id":"A959","pred":"tao:has_database_id","subj":"959","obj":"MESH:D009102"},{"id":"A960","pred":"tao:has_database_id","subj":"960","obj":"MESH:D007249"},{"id":"A961","pred":"tao:has_database_id","subj":"961","obj":"MESH:D057772"},{"id":"A962","pred":"tao:has_database_id","subj":"962","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T32","span":{"begin":206,"end":211},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T15","span":{"begin":206,"end":211},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T183","span":{"begin":162,"end":166},"obj":"Disease"},{"id":"T184","span":{"begin":251,"end":263},"obj":"Disease"},{"id":"T185","span":{"begin":277,"end":283},"obj":"Disease"}],"attributes":[{"id":"A183","pred":"mondo_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A184","pred":"mondo_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A185","pred":"mondo_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T203","span":{"begin":98,"end":99},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T204","span":{"begin":206,"end":211},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T231","span":{"begin":63,"end":72},"obj":"Chemical"},{"id":"T232","span":{"begin":63,"end":70},"obj":"Chemical"},{"id":"T233","span":{"begin":400,"end":409},"obj":"Chemical"},{"id":"T234","span":{"begin":400,"end":407},"obj":"Chemical"}],"attributes":[{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_21241"},{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_21241"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T21","span":{"begin":251,"end":263},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T37","span":{"begin":151,"end":157},"obj":"Phenotype"}],"attributes":[{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0100806"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"LitCovid-sentences","denotations":[{"id":"T204","span":{"begin":0,"end":284},"obj":"Sentence"},{"id":"T205","span":{"begin":285,"end":415},"obj":"Sentence"},{"id":"T206","span":{"begin":416,"end":502},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}

{"project":"2_test","denotations":[{"id":"32040667-31573637-47981317","span":{"begin":411,"end":413},"obj":"31573637"},{"id":"T12849","span":{"begin":411,"end":413},"obj":"31573637"}],"text":"The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (n = 167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [40]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed."}